• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Early-stage

New pharma fund acquires Xenova

  • Guy
  • 24 June 2005
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

A new private equity fund led by Stephen Evans-Freke and John Mayo has announced its first investment with the takeover of Xenova.

Celtic Pharmaceutical Holdings, LP, a newly formed private equity investment fund targeting the pharmaceutical industry, has announced the launch of the fund and its first investment with the agreed takeover of the UK biotechnology company, Xenova Plc, for a total consideration of approximately £20m.

Led by Stephen Evans-Freke and John Mayo, both of whom have outstanding track records of delivering high returns to investors in the pharmaceutical industry, Celtic Pharma has been formed to invest directly in the acquisition of pharmaceutical products which are in the final stages of their development and regulatory approval. It will target small biotechnology companies, public or private, that have commercially attractive, novel drugs in late Phase II or Phase III clinical development, as well as buying Phase III products from pharmaceutical or biotech companies or divisions of such companies. In some cases, Celtic Pharma will buy geographical rights to products (for example, in the US, Europe or Japan) where the rights are not being exploited in these markets.

Acquisitions will be funded through a combination of fund equity, mezzanine financing and the securitisation of royalties on already licensed products. Celtic Pharma’s objective is to assemble a diversified portfolio of 12-18 late stage drug development programmes which it will fund and manage through the final stages of clinical and regulatory approval, including establishing manufacturing arrangements and other preparations for market launch. Products that have been approved, or prior to approval but ready for pre-marketing, will then be auctioned to established pharmaceutical companies.

Celtic Pharma’s management intends to run the fund on a rigorous “virtual” outsourcing model, managing and controlling the various programmes in-house but using outsourced providers in the management of clinical trials, manufacturing, QC/QA and other specialist services where required.

Celtic Pharma has assembled an exceptionally strong in-house team with the requisite skills in both product evaluation and late stage pharmaceutical programme management, as well as in business development, mergers and acquisitions and finance. In addition to the in-house team, Celtic Pharma has also gathered a number of leading experts from the worlds of business and pharmaceutical product development to join its Business Advisory and Medical Advisory Boards.

To date, some $125m has been committed and closed into the Celtic Pharma fund from investors around the world, with significant further indicated amounts to be closed in over the coming months. It is Celtic Pharma’s objective to grow this to $300m by the end of this year and to over $1bn in the 2006/07 timeframe.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Early-stage

More on Early-stage

Europe InsurTech PE VC Investment
Sidekick spinoffs: Insurtech scale-ups attract PE interest

Investment set to break EUR 1.1bn mark this year as sponsors seek for rising stars

  • Data Snapshot
  • 03 August 2022
Mikko Mottonen  Jan Goetz  Kuan Yen Tan and Juha Vartiainen of IQM Quantum Computers
World Fund leads EUR 128m raise for quantum computing group IQM

Series-A2 for Finnish startup focused on combating the climate crisis also backed by the EIB

  • Early-stage
  • 22 July 2022
Grocery delivery services
Gorillas raises circa USD 1bn in Delivery Hero-led Series C

New funding comes just seven months after a Series B, with the company doubling in value

  • Early-stage
  • 19 October 2021
French venture and growth capital deals in excess of EUR 100m
French mega-rounds shoot up in 2021

France has already seen as many rounds of EUR 100m and above than in 2019 and 2020 combined, Unquote Data shows

  • Data Snapshot
  • 22 September 2021

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013